Wang Youqiao, Wang Zeyi, Liu Ziyi, Li Jinyan, Yang Shuo, Zhao Yuxuan, Huang Yangmei, Liao Chenyang, Zhang Yiqiu, Zhao Jiaojiao, Zhou Weilin, Zhou Binhua, Yue Xin, Zhou Qiang, Bu Xianzhang
School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.
State Key Laboratory of Chemical Oncogenomics, Guangdong Provincial Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen, China.
Nat Commun. 2025 Aug 30;16(1):8128. doi: 10.1038/s41467-025-63458-3.
Amyloid-β (Aβ), a key driver of Alzheimer's disease (AD) pathogenesis, possesses diverse harmful and clearance-resistant structures that present substantial challenges to therapeutic development. Here, we demonstrate that modulating Aβ morphology, rather than Toll-like receptor 2 (TLR2)-dependent microglia activation, is essential for effective phagocytosis of Aβ species by microglia. By developing a bifunctional mechanistic probe (P2CSKn) designed to remodel Aβ and activate TLR2, we show it restructures soluble Aβ (sAβ) and fibrillar Aβ (fAβ) into less toxic hybrid aggregates (hPAβ). Critically, this structural remodeling protects microglia from Aβ toxicity while enabling robust phagocytosis. Moreover, although TLR2 activation mildly enhances Aβ uptake, it concurrently triggers detrimental inflammation that negates its benefits. Our findings establish morphological remodeling as the critical determinant of effective Aβ clearance and suggest a morphology-focused strategy for developing safe therapeutics for Aβ-related diseases.
淀粉样β蛋白(Aβ)是阿尔茨海默病(AD)发病机制的关键驱动因素,具有多种有害且难以清除的结构,这给治疗药物的研发带来了巨大挑战。在此,我们证明,调节Aβ形态对于小胶质细胞有效吞噬Aβ物种至关重要,而非依赖Toll样受体2(TLR2)的小胶质细胞激活。通过开发一种旨在重塑Aβ并激活TLR2的双功能机制探针(P2CSKn),我们表明它能将可溶性Aβ(sAβ)和纤维状Aβ(fAβ)重构为毒性较小的混合聚集体(hPAβ)。至关重要的是,这种结构重塑可保护小胶质细胞免受Aβ毒性,同时实现强大的吞噬作用。此外,尽管TLR2激活会轻微增强Aβ摄取,但它同时会引发有害炎症,抵消其益处。我们的研究结果将形态重塑确立为有效清除Aβ的关键决定因素,并提出了一种以形态为重点的策略,用于开发针对Aβ相关疾病的安全治疗方法。